Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...
A drug combination from Johnson & Johnson outperformed AstraZeneca’s Tagrisso in slowing the worsening of newly diagnosed lung cancer. But it’ll take more than a tumor progression win to dethrone the ...
Tagrisso plus chemotherapy improved progression-free survival in EGFR-positive NSCLC patients compared to placebo plus chemotherapy, with median survival of 8.4 vs. 4.4 months. Central nervous system ...
Tagrisso, with chemotherapy, reduced the risk of disease progression or death by 38% by investigator assessment vs. Tagrisso monotherapy. Median progression-free survival was 25.5 months in Tagrisso ...
Results underscore TAGRISSO as 1st-line standard of care and backbone therapy in EGFRm lung cancer across stages WILMINGTON, Del.--(BUSINESS WIRE)-- Positive results from the final overall survival ...
Around 30,000 people annually in the U.S. with non-small cell lung cancer (NSCLC) also get diagnosed with specific epidermal growth factor receptor (EGFR) gene mutations, a condition that affects ...
SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity Susan Galbraith, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback